CSIMarket
 

Propanc Biopharma Inc   (PPCH)

Propanc Biopharma Inc 's

Competitiveness




 

PPCH Sales vs. its Competitors Q3 2026



Comparing the current results to its competitors, Propanc Biopharma Inc reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 49.29 %, recorded in the same quarter.

List of PPCH Competitors





Revenue Growth Comparisons




Net Income Comparison


Propanc Biopharma Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<<  PPCH Stock Performance Comparisons


Propanc Biopharma Inc 's Comment on Competition and Industry Peers


The global ovarian cancer treatment market features key competitors including AbbVie Inc., AstraZeneca PLC (Acerta Pharma), Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co., Ltd., Gradalis, Inc., GSK plc (formerly GlaxoSmithKline plc, Tesaro), Incyte Corporation, Kazia Therapeutics Limited (formerly Novogen Limited), MacroGenics, Inc., Merck & Co., Inc., Novartis AG, Oncotelic Therapeutics, Inc. (formerly Mateon Therapeutics, Inc.), Pfizer Inc., Pharma Mar S.A., Roche Holding AG, and Vivesto AB (formerly Oasmia Pharmaceutical AB). The biotechnology and pharmaceutical sectors involve competition among major companies, academic institutions, governmental agencies, and research organizations. Competitive factors include treatment efficacy, safety, convenience, generic alternatives, reimbursement policies, and regulatory approval timelines, all influencing market positioning and competitiveness.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Propanc Biopharma Inc




Zymeworks Inc
Share Performance



+14.69%
This Quarter



Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,915.345 mill. $ 37.127 mill. $ -149.992 mill.


Oramed Pharmaceuticals Inc
Share Performance



+1.09%
30 Days



Oramed Pharmaceuticals Inc
Profile

Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.

More about Oramed Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 196.356 mill. $ - mill. $ 174.864 mill.


Oncolytics Biotech Inc
Share Performance



-21.55%
This Year



Oncolytics Biotech Inc
Profile

Oncolytics Biotech Inc operates as a biotechnology company engaged in the development and commercialization of oncolytic viruses as potential therapeutics for the treatment of various cancers. Its business model revolves around identifying and acquiring intellectual property rights, conducting preclinical and clinical studies, and collaborating with pharmaceutical and biotechnology companies for the development and commercialization of its products. The company aims to deliver innovative and targeted cancer therapies to improve patient outcomes globally.

More about Oncolytics Biotech Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 92.056 mill. $ - mill. $ -52.721 mill.


Nextcure Inc
Share Performance



+190.60%
This Quarter



Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 32.018 mill. $ - mill. $ -42.748 mill.


Nuvalent Inc
Share Performance



+48.63%
One Year



Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9,751.979 mill. $ - mill. $ -450.074 mill.

32 more competitors available

Sign in to see all competitors

Sources: Propanc Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Propanc Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.